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Background: The Japanese Heart Rhythm Society (JHRS) conducted a nationwide survey of catheter
ablation of atrial ﬁbrillation (AF) in Japan, the Japanese Catheter Ablation Registry of Atrial Fibrillation
(J-CARAF). In this report, to offer a perspective on the current status of hybrid AF therapy, we focus on
antiarrhythmic drug (AAD) therapy before and after AF ablation.
Methods: The JHRS requested electrophysiology centers in Japan to retrospectively register the compre-
hensive data of each AF ablation session performed in September 2011, March 2012, or September 2012.
Results: A total of 179 EP centers submitted data for 3373 sessions. The average patient age was
62.2710.6 years, and 76.1% (2587) were male. Patients with paroxysmal AF (PAF) consisted of 64.4% of
total patients. The average number of AADs used before AF ablation was 1.1370.96. Among 2173 PAF
patients, 454 subjects (20.9%) underwent AF ablation without preceding AAD therapy.
At the time of discharge, 40.3% of PAF patients were given one or more AAD, while 63.0% of persistent
AF patients and 71.5% of long-standing-persistent AF patients left the hospital with an AAD (po0.0001).
Bepridil was most frequently prescribed (17.4%), speciﬁcally in non-PAF patients (PAF 10.5% vs. non-PAF
30.3%, po0.0001). Amiodarone was used in 5.8% of the patients. Among 148 subjects (4.5%) treated with
multiple AADs, 131 were taking bepridil.
Conclusions: Approximately 20% of PAF ablations were performed without preceding AAD therapy.
The post-procedural AAD regimen was appreciably dependent on the AF type.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Catheter ablation has become an effective and established
therapy for atrial ﬁbrillation (AF). Many clinical studies have
surveyed various aspects of AF ablation, such as the incidence of
complications, success rate, and cost effectiveness. Constant effort
is mandatory to conﬁrmwhether catheter ablation in each country
is performed in a way that meets the international standard [1].
The Japanese Heart Rhythm Society (JHRS) carried out a nation-
wide survey of AF-related catheter ablation: the Japanese Catheter
Ablation Registry of Atrial Fibrillation (J-CARAF). The aim of this
survey was to collect the objective data to manage the perfor-
mance and safety of AF ablation in Japan.
Although some clinical studies have reported that AF ablation
is a better choice than antiarrhythmic drug (AAD) therapy for
the maintenance of sinus rhythm, AADs are often prescribed
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empirically to prevent AF recurrence or to alleviate the AF burden
even after catheter ablation [2–5]. In this report, we focus on the
use of AADs before and after AF ablation. The aim of this analysis
was to offer a perspective of the current status of hybrid AF
therapy in Japan.
2. Material and methods
The method of this survey was previously reported [6]. In short,
the survey was performed retrospectively using an online ques-
tionnaire. JHRS members were notiﬁed by e-mail. Data were
collected on patients' backgrounds, methods of pulmonary vein
isolation and related techniques, complications, and pre- and post-
procedural pharmacological treatments in AF ablation procedures
performed in September 2011, May 2012, or September 2012.
Patient data included age, gender, AF ablation procedure history,
AF type (paroxysmal [PAF], persistent, or long-standing [LS]
persistent), frequency of AF attacks of PAF, risk factors associated
with thromboembolism, structural heart disease, and echocardio-
graphic parameters.
The continuous variables with a normal distribution were
expressed as the mean7SD. Comparison of categorical variables
was performed using a Tukey's test.
3. Results
One hundred and seventy-nine EP centers reported AF ablation
data (Appendix A). Information from a total of 3373 sessions was
collected. Table 1 shows the patients' backgrounds. The average
patient age was 62.2710.6 years, and 76.1% (2587) were male. Of
all sessions, 77.4% were ﬁrst AF ablation sessions, 19.1% were
second sessions, and 3.5% were subsequent sessions. Patients
with PAF constituted 64.4% (n¼2173), while persistent and LS-
persistent AF were 21.7% and 13.8% (n¼733 and 467), respectively.
Clinical proﬁles of three AF types are shown in Table 1. Patients
with PAF had a history of previous pharmacological antiarrhyth-
mic treatment more frequently compared to that in patients with
persistent AF and LS-persistent AF.
In total, 79.5% of patients (2560/3373) received prior AAD
therapy. The average number of antiarrhythmic drugs used before
AF ablation was 1.1370.96. Table 2 shows the distribution of the
number of AADs used in each of the AF types. Among 2173 PAF
patients, 454 subjects (20.9%) underwent AF ablation without
preceding AAD therapy. The number of subjects treated with each
AAD is shown in Table 3.
At the time of discharge, 49.6% of patients were treated with
one or two AADs. A larger proportion of persistent AF patients and
LS-persistent AF patients were given AADs than PAF patients
(Fig. 1). Namely, 40.3% of PAF patients were discharged under
AAD treatment, while 63.0% of persistent AF patients and 71.5% of
LS-persistent AF patients left the hospital with AAD therapy
(po0.0001). Bepridil was most frequently prescribed (17.4%,
Table 4). Flecainide and pilsicainide were used in 9.4% and 8.0%
Table 1
Gender, age, and previous AADs.
No. Age Male (%) Previous AAD (%) No. of AADs
PAF 2173 62.6710.8 73.7 79.1 1.1770.94
Persist AF 733 62.0710.0 77.8nn 74.6nn 1.1470.99
LS-Persist AF 467 60.0710.4n 84.6 63.0 0.9170.94n
PAF: paroxysmal atrial ﬁbrillation, Persist AF: persistent atrial ﬁbrillation, LS-Persist
AF: long-standing persistent atrial ﬁbrillation.
n po0.01 vs. PAF and Persist AF.
nn po0.05 vs. PAF, po0.01 vs. LS-Persist AF.
Table 2
The number of AADs used before catheter ablation.
No. of AAD Total PAF Persist AF LS-Persist AF
0 813 24.1% 454 20.9% 186 25.4% 173 37.0%
1 1706 50.6% 1157 53.2% 342 46.7% 207 44.3%
2 579 17.2% 382 17.6% 145 19.8% 52 11.1%
3 191 5.7% 124 5.7% 41 5.6% 26 5.6%
Z4 84 2.5% 56 2.6% 19 2.6% 9 1.9%
Total 3373 100% 2173 100% 733 100% 467 100%
Table 3
Antiarrhythmic drugs used prior to catheter ablation in 3373 subjects.
Disopyramide Cibenzoline Aprindine Pilsicainide Flecainide
245 553 172 924 505
7.3% 16.4% 5.1% 27.3% 14.9%
Propafenone Bepridil D,L-Sotalol Amiodarone Others
119 752 35 244 270
3.5% 22.3% 1.0% 7.2% 8.0%
The number of subjects treated with each drug is expressed as a percent of 3373.
Fig. 1. Proportion of patients with one or more antiarrhythmic drugs at the time of
discharge. PAF patients were discharged more frequently without AAD than non-
PAF patients. npo0.01 vs. Persist AF and LS-Persist AF, nnpo0.05 vs. LS-Persist AF.
Table 4
Antiarrhythmic treatment at the time of discharge.
Total no. PAF Persist-AF LS-Persist AF Total Percent
2173 733 467 3373
Disopyramide 24 8 2 34 1.0%
Cibenzoline 133 43 18 194 5.8%
Pirmenol 9 0 2 11 0.3%
Aprindine 35 33 16 84 2.5%
Pilsicainide 205 45 19 269 8.0%
Flecainide 172 88 56 316 9.4%
Propafenone 56 13 15 84 2.5%
Bepridil 230 197 167 594 17.6%
Amiodarone 51 81 65 197 5.8%
Others 28 12 9 49 1.5%
Treated with AAD 876 (40.3%)n 462 (63.0%)nn 334 (71.5%) 1672 49.6%
Single 815 (37.5%)n 413 (56.3%)nn 299 (64.0%) 1527 45.3%
Combined 61 (2.8%)n 49 (6.7%) 35 (7.5%) 145 4.3%
n po0.01 vs. Persist AF and LS-Persist AF.
nn po0.05 vs. LS-Persist AF.
Y. Murakawa et al. / Journal of Arrhythmia 30 (2014) 362–366 363
of patients, respectively. Amiodarone was prescribed in 5.8% of
patients.
Combined use of two AADs was more frequent in persistent
(6.7%) and LS-persistent AF (7.5%) patients than in PAF patients
(2.8%, po0.01 vs. persistent and LS-persistent AF). Among 148
subjects treated with multiple AADs, 131 received bepridil. Aprin-
dine (n¼42, 32.1%), pilsicainide (n¼32, 24.4%), and ﬂecainide
(n¼24, 18.3%) were preferred as a counterpart of combined AAD
therapy.
Fig. 2 compares the distributions of AADs of different classes
prescribed at the time of discharge in the three AF types. The
choice of bepridil was dependent on the type of AF (PAF 10.6% vs.
non-PAF 30.3%, po0.0001), while class Ic AADs were used
comparably among the three AF types. Fig. 3 compares the
distribution of three class Ic AADs in each AF type. Pilsicainide
was used mainly in PAF patients. Flecainide was less frequently
used in PAF patients than in those with persistent or LS-persistent
AF (po0.01).
A small number of PAF patients were given amiodarone (2.3%).
On the other hand, more than 10% of persistent and LS-persistent
AF patients were discharged with amiodarone (11.1% and 13.9%).
4. Discussion
The major ﬁndings of the present study are (1) about 20% of
PAF patients underwent AF ablation without a history of AAD
therapy, (2) after AF ablation, about half of patients were dis-
charged with AADs, (3) the type of AF was related to the ratio of
subjects treated with AADs at the time of discharge, (4) persistent
and LS-persistent AF were associated with more frequent use of
bepridil or amiodarone, and multiple AAD regimen, and (5) class Ic
AADs were consistently used both before and after AF ablation.
4.1. AADs before AF ablation
AF ablation has become a standard treatment to restore and
maintain sinus rhythm. It is not easy to compare the clinical
beneﬁts between AADs and catheter ablation because multiple
aspects, such as symptoms, prognosis, safety, and cost effective-
ness, are involved in the evaluation of their merits [2]. Practically,
it is rational to consider that pharmacological and non-
pharmacological treatments work in a cooperative manner to
abolish AF or reduce the incidence and duration of arrhythmic
events [3,7].
In the present study, we found that one-fourth of AF patients
underwent ablation without a history of preceding pharmacolo-
gical therapy. Because there were marked differences in the ratios
of previous AAD therapy among the three AF types (20.9%, 25.4%,
and 37.0%), physicians may have assumed that AADs are not potent
enough to restore sinus rhythm in patients with prolonged AF. It is
also conceivable that improved outcomes of AF ablation encour-
aged physicians to choose catheter ablation as a ﬁrst-line therapy
for arrhythmia [8].
In an earlier report, Winkle et al. assessed the number of AADs
that failed prior to initial ablation of PAF or persistent AF [9]. They
found that 195 (20.7%) out of 942 patients underwent AF ablation
without documented failure of any AAD therapy. Considerable
region-dependent or institute-dependent variation may exist in
the use of AADs and catheter ablation [10]. However, it seems that
AF ablation is gradually becoming a reasonable choice, even in
those without preceding AAD treatment.
4.2. Signiﬁcance of AADs after AF ablation
AADs are widely used to supplement the efﬁcacy of AF ablation.
Physicians may have a speciﬁc intention to suppress the early
recurrence of AF during an electrically unstable period [4,5].
Antiarrhythmic medication in the ﬁrst six weeks immediately
following AF ablation prevented early recurrence of AF [4]. How-
ever, this short-term empirical AAD therapy failed to contribute to
the maintenance of sinus rhythm at six months after the proce-
dure [5].
The efﬁcacy of AF ablation itself is not readily known in the
presence of concomitant AAD treatment. Physicians are required
to speculate about the “clinical outcome of AF ablation” through
temporal proﬁles of the arrhythmia on an individual basis. For the
time being, it is not clearly deﬁned to what extent AAD should be
used to consolidate or supplement the effect of AF ablation.
In this registry, we did not assess whether physicians used
post-ablation AADs aiming at their long-lasting legacy effects or
not. We have a plan to accumulate one-year follow-up data of
registered subjects. By analyzing these data, it may be possible to
obtain some insight into physicians' intentions to use AAD at the
time of discharge and into the signiﬁcance of post-ablation AAD
therapy.
5. Conclusions
The proportion of patients discharged with AADs was depen-
dent on the AF type. AF duration was reﬂected in the choice of
AADs. Although physicians' intentions of the prescription of AADs
were not included in the survey, it seems that physicians modify
the post-ablation pharmacological therapy in a tailored approach.
We hope that observations during the follow-up period will offer
Fig. 2. Antiarrhythmic drugs at the time of discharge. Bepridil and amiodarone
were more extensively used in non-PAF subjects. npo0.01 vs. PAF, nnpo0.01 vs.
PAF and LS-Persist AF, †po0.01 vs. Persist AF and LS-Persist AF.
Fig. 3. Class Ic antiarrhythmic drugs at the time of discharge. Pilsicainide was
preferred in PAF patients. npo0.01 vs. Persist AF and LS-Persist AF, nnpo0.01 vs.
Persist AF, po0.01 LS-Persist AF.
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some insight into the signiﬁcance of post-ablation antiarrhythmic
treatment.
Conﬂict of interest
None of authors have conﬂicts of interest to declare.
Appendix A
Teine Keijinkai Hospital (Sapporo)
Sapporo Medical University School of Medicine (Sapporo)
Hokkaido University (Sapporo)
Hokkaido Social Insurance Hospital (Sapporo)
Hokkaido Medical Center (Sapporo)
Hokkaido Cardiovascular Hospital (Sapporo)
Hokko Memorial Hospital (Sapporo)
Asahikawa Medical University (Asahikawa)
Kushiro Kojinkai Memorial Hospital (Kushiro)
Akita Medical Center (Akita)
Hirosaki University (Hirosaki)
Ohta Nishinouchi Hospital (Koriyama)
Sendai Kousei Hospital (Sendai)
Tohoku University Hospital (Sendai)
Sendai Cardiovascular Center (Sendai)
Sendai City Hospital (Sendai)
Yamagata University (Yamagata)
Surugadai Nihon University Hospital (Tokyo)
The Jikei University (Tokyo)
The Cardiovascular Institute (Tokyo)
Tokyo Medical and Dental University (Tokyo)
Nippon Medical School (Tokyo)
IMS Katsushika Heart Center (Tokyo)
Edogawa Hospital (Tokyo)
Tokyo Rinkai Hospital (Tokyo)
Showa University School of Medicine (Tokyo)
Toho University Omori Medical Center (Tokyo)
Tokyo Metropolitan Hiroo Hospital (Tokyo)
Toho University Ohashi Medical Center (Tokyo)
Self-Defense Forces Central Hospital (Tokyo)
Tokyo Medical University (Tokyo)
Keio University (Tokyo)
Tokyo Women's Medical University (Tokyo)
Nihon University Itabashi (Tokyo)
The University of Tokyo (Tokyo)
Itabashi Chuo Medical Center (Tokyo)
Kyorin University (Tokyo)
National Disaster Medical Center (Tokyo)
Tokai University Hachioji Hospital (Tokyo)
Ome Municipal General Hospital (Tokyo)
Kawasaki Municipal Tama Hospital (Kawasaki)
St. Marianna University School of Medicine (Kawasaki)
Yokohama Rosai Hospital (Yokohama)
Yokohama General Hospital (Yokohama)
Showa University Fujigaoka Hospital (Yokohama)
Kitasato University (Sagamihara)
Yokohama City Minato Red Cross Hospital (Yokohama)
Yokohama Minami Kyosai Hospital (Yokohama)
Yokosuka Kyosai Hospital (Yokosuka)
Hayama Heart Center (Hayama)
Shonan Kamakura General Hospital (Kamakura)
Odawara Cardiovascular Hospital (Odawara)
Toshiba Rinkan Hospital (Saagamihara)
Hiratsuka Kyosai Hospital (Hiratsuka)
New Tokyo Hospital (Matsudo)
Matsudo City Hospital (Matsudo)
Kimitsu Chuo Hospital (Kisarazu)
Kameda Medical Center (Kamogawa)
Tsuchiura Kyodo General Hospital (Tsuchiura)
Tsukuba Memorial Hospital (Tsukuba)
University of Tsukuba (Tsukuba)
Jichi Medical University School of Medicine (Simotsuke)
Saitama Red Cross Hospital (Saitama)
Saitama Medical University International Medical Center
(Kawagoe)
Takase Clinic (Takasaki)
Gunma Cardiovascular Center (Maebashi)
Gunma University (Maebashi)
Nagano Chuo Hospital (Nagano)
Nagano Red Cross Hospital (Nagano)
Matsumoto Kyoritsu Hospital (Matsumoto)
Shinshu University (Matsumoto)
Yamanashi Kosei Hospital (Yamanashi)
Niigata University (Niigata)
Okamura Memorial Hospital (Shimizu)
Shizuoka Medical Center (Shizuoka)
Shizuoka Hospital (Shizuoka)
Shizuoka General Hospital (Shizuoka)
Shizuoka Saiseikai General Hospital (Shizuoka)
Hamamatsu University School of Medicine (Hamamatsu)
Hamamatsu Medical Center (Hamamatsu)
Toyohashi Heart Center (Toyohashi)
Anjo Kosei Hospital (Anjo)
Kariya Toyota General Hospital (Kariya)
Nagoya Ekisaikai Hospital (Nagoya)
Social Insurance Chukyo Hospital (Nagoya)
Nagoya City East Medical Center (Nagoya)
Nagoya University (Nagoya)
Nagoya Daini Red Cross Hospital (Nagoya)
Toyota Kosei Hospital (Toyota)
Fujita Health University (Toyoake)
Aichi Medical University (Nagakute)
Konan Kosei Hospital (Konan)
Komaki City Hospital (Komaki)
Ichinomiyanishi Hospital (Ichinomiya)
Gifu Prefectural General Medical Center (Gifu)
Gifu University (Gifu)
Ogaki Municipal Hospital (Ogaki)
Mie Chuo Medical Center (Tsu)
Mie University (Tsu)
Mie Heart Center (Meiwa)
Fukui Cardiovascular Center (Fukui)
Fukui Prefectural Hospital (Fukui)
Kanazawa Medical University (Kanazawa)
Ishikawa Prefectural Central Hospital (Kanazawa)
Kanazawa University (Kanazawa)
Toyama University (Toyama)
Toyama Prefectural Central Hospital (Toyama)
Shiga University of Medical Science (Otsu)
Shiga Medical Center for Adults (Moriyama)
Sakurabashi Watanabe Hospital (Osaka)
Kitano Hospital (Osaka)
Osaka City General Hospital (Osaka)
Osaka Police Hospital (Osaka)
Osaka Red Cross Hospital (Osaka)
Osaka City University (Osaka)
Higashisumiyoshi Morimoto Hospital (Osaka)
Osaka Saiseikai Izuo Hospital (Osaka)
Osaka Koseinenkin Hospital (Osaka)
Tominaga Hospital (Osaka)
Osaka General Medical Center (Osaka)
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Osaka University (Osaka)
National Cerebral and Cardiovascular Center (Suita)
Osaka Medical College (Takatsuki)
Kansai Medical University Hirakata Hospital (Hirakata)
Shiroyama Hospital (Habikino)
Osaka Rosai Hospital (Sakai)
Kishiwada Tokushukai Hospital (Kishiwada)
Takeda Hospital (Kyoto)
Japanese Red Cross Kyoto Daini Hospital (Kyoto)
Kyoto Prefectural University of Medicine (Kyoto)
Kyoto University (Kyoto)
Kyoto-Katsura Hospital (Kyoto)
Gakkentoshi Hospital (Seika)
Maizuru Kyosai Hospital (Maizuru)
Nara Hospital Kinki University Faculty of Medicine (Ikoma)
Takai Hospital (Tenri)
Tenri Hospital (Tenri)
Yamato Kashihara Hospital (Kashihara)
Nara Medical University (Kashihara)
Japanese Red Cross Wakayama Medical Center (Wakayama)
Kobe University (Kobe)
Kobe City Medical Center General Hospital (Kobe)
Kansai Rosai Hospital (Amagasaki)
Hyogo College of Medicine (Nishinomiya)
Hyogo Brain and Heart Center (Himeji)
Tottori Prefectural Central Hospital (Tottori)
Matsue Red Cross Hospital (Matsue)
Shimane Prefectural Central Hospital (Izumo)
Sakakibara Heart Institute of Okayama (Okayama)
Okayama University (Okayama)
Okayama Medical Center (Okayama)
Kurashiki Central Hospital (Kurashiki)
Fukuyama Cardiovascular Hospital (Fukuyama)
Hiroshima City Hospital (Hiroshima)
Hiroshima Prefectural Hospital (Hiroshima)
Tokuyama Central Hospital (Tokuyama)
Yamaguchi University (Ube)
Kagawa Prefectural Shirotori Hospital (Higashikagawa)
Tokushima Red Cross Hospital (Komatsushima)
Oe Kyodou Hospital (Yoshinogawa)
Ehime University (Touon)
Kokura Memorial Hospital (Kitakyusyu)
Kyushu Kosei Nenkin Hospital (Kitakyusyu)
University of Occupational and Environmental Health
(Kitakyusyu)
Saiseikai Fukuoka General Hospital (Fukuoka)
Kyushu Medical Center (Fukuoka)
Kyushu University (Fukuoka)
Fukuoka Sanno Hospital (Fukuoka)
Saiseikai Futsukaichi Hospital (Chikushino)
Saiseikai Kumamoto Hospital (Kumamoto)
Japanese Red Cross Kumamoto Hospital (Kumamoto)
Kumamoto Chuo Hospital (Kumamoto)
EP Expert Doctors-Team Tsuchiya (Kumamoto)
Oita Medical Center (Oita)
Oita University (Oita)
Miyazaki Medical Association Hospital (Miyazaki)
Kagoshima Medical Center (Kagoshima)
Tomishiro Central Hospital (Tomishiro)
Shonan Hospital (Okinawa)
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